First National Bank of Mount Dora Trust Investment Services decreased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 59.1% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 12,684 shares of the company's stock after selling 18,345 shares during the quarter. First National Bank of Mount Dora Trust Investment Services' holdings in Johnson & Johnson were worth $2,104,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently modified their holdings of the company. WealthTrak Capital Management LLC bought a new position in shares of Johnson & Johnson in the 4th quarter worth $26,000. Mountain Hill Investment Partners Corp. bought a new position in shares of Johnson & Johnson in the 4th quarter worth $29,000. Conquis Financial LLC bought a new position in Johnson & Johnson during the 4th quarter valued at $33,000. Bernard Wealth Management Corp. bought a new position in Johnson & Johnson during the 4th quarter valued at $36,000. Finally, Runnymede Capital Advisors Inc. bought a new position in Johnson & Johnson during the 4th quarter valued at $38,000. Institutional investors and hedge funds own 69.55% of the company's stock.
Johnson & Johnson Price Performance
NYSE:JNJ traded up $0.24 during mid-day trading on Friday, hitting $156.90. 6,587,488 shares of the stock traded hands, compared to its average volume of 7,963,253. The business's 50-day moving average price is $153.84 and its 200 day moving average price is $153.72. The company has a market cap of $377.52 billion, a PE ratio of 23.59, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. On average, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.31%. The ex-dividend date was Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is currently 57.84%.
Wall Street Analyst Weigh In
Several brokerages have weighed in on JNJ. Barclays dropped their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 17th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Raymond James decreased their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research report on Monday, April 14th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 5th. Finally, Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $170.88.
Check Out Our Latest Stock Analysis on Johnson & Johnson
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
